Abdominal metastases of primary extremity soft tissue sarcoma: A systematic review

Abstract

BACKGROUND

Despite the fact that about one third of patients with primary localized extremity soft tissue sarcoma (eSTS) will develop metastatic disease, abdominal metastases (AM) and retroperitoneal metastases (RM) constitute rare events. There is no clear consensus on how to achieve follow-up on patients with primary localized eSTS following curative resection, especially regarding the surveillance of potential AM/RM.

AIM

To systematically analyse incidence, diagnosis, treatment and outcome of AM/RM in eSTS patients.

METHODS

In this systematic review, 899 studies available in PubMed and published between 2000 and 2018 were screened, identifying 17 original articles focused on AM or RM in eSTS. Article selection was based on the PRISMA guidelines, using the search terms (abdominal metastasis AND soft tissue sarcoma) and (soft tissue sarcoma metastasis abdomen). All studies published between January 1, 2000 and December 31, 2018 were screened. Further articles were identified by cross-searching article references, with the final search date being February 18, 2019. Due to limited data and the different reporting techniques used, the present review focused on descriptive analysis of the included studies.

RESULTS

Of the 17 studies included, six original articles reported on incidence ± diagnosis, therapy and outcome in AM and RM, whilst three original and eight case reports focused on diagnostic pathway, therapeutic procedures or outcomes without allowing conclusions regarding incidence of AM and RM. According to the former six studies, incidence of AM ranged from 0.9%-5.6% in patients with miscellaneous histological subtypes, and up to 12.1% in patients with myxoid liposarcoma. The most common histological subtypes that developed AM or RM were (myxoid) liposarcoma and leiomyosarcoma, but also rare subtypes such as epithelioid sarcoma, myxofibrosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumour had been reported to develop AM/RM. Surgery for AM/RM was performed in five of eight case-reports (62.5%) and in 20.8%-100.0% of original articles. In particular, patients with hepatic metastases undergoing metastasectomy had a survival benefit compared to patients treated with chemotherapy or best supportive care (> 3 years vs < 6 mo).

CONCLUSION

Patients with eSTS should undergo surveillance with abdominal ultrasonography/computed tomography, or even whole-body-magnetic resonance imaging to detect AM/RM at an early stage.

Key Words: Extremity soft tissue sarcoma, Abdominal metastasis, Retroperitoneal metastasis, Diagnosis, Treatment, Outcome

Core tip: Incidence of abdominal (AM) and retroperitoneal metastases (RM) in patients with primary extremity soft tissue sarcoma has been reported to be as high as 12.1%, depending on the histological subtypes and screening methods used. Patients undergoing metastasectomy seem to have a clear survival benefit. Consequently, regular abdominal check-ups with abdominal computed tomography-scans, ultrasonography or even whole-body-magnetic resonance imaging are preferable in order to detect AM/RM at an early, potentially resectable stage.

INTRODUCTION

Extremity soft tissue sarcomas (eSTS) have an estimated incidence of 4-5 per 100,000 persons per year in Europe, with liposarcoma and leiomyosarcoma being the most common histological subtypes[1,2]. About one third of patients with primary localized eSTS will develop metastatic disease during follow-up, most frequently in the lungs[3]. Surveillance for eSTS patients who have undergone curative surgery follows a heuristic approach, with regular check-ups in 3-4-mo intervals for the first 3 years, biannually up to the end of the 5^th year and annually thereafter[4]. Whilst computed tomography (CT)-scans or X-rays of the thorax as well as magnetic resonance imaging (MRI)-scans of the primary tumour sites are well-established, abdominal surveillance with ultrasonography or abdominal CT scans is performed inconsistently[4]. It is well-established that eSTS can metastasize to virtually any body region, including brain, bone, abdomen and retroperitoneum. The occurrence of these metastases, however, is considered a rare event. As a result, diagnostic workup via e.g., brain MRI or abdominal CT scans are often only performed if patients are symptomatic.

Thus, the main objective of this systematic literature review is to summarize the evidence concerning incidence, diagnosis, treatment and outcome of abdominal metastases (AM) and retroperitoneal metastases (RM) in patients with primary eSTS.

MATERIALS AND METHODS

Literature search

All studies published between January 1, 2000 and December 31, 2018 were included in the systematic review. Studies published before 2000 were excluded, given the fact that diagnostic (pathology, radiology) and treatment modalities [radiotherapy (RTX), chemotherapy (CTX)] have changed – and markedly improved – over time. Given that AM and RM in eSTS are rare events, retrospective cohort studies and case-series, as well as single case reports, were considered eligible. PubMed was used as the primary database. Further potential articles were identified by cross-searching article references as well as meeting abstracts. The final search date was February 18, 2019.

The following search terms were used in PubMed: (abdominal metastasis AND soft tissue sarcoma) and (soft tissue sarcoma metastasis abdomen). The structure of the systematic review was based on PRISMA guidelines[5]. Studies were initially screened by their title, followed by the abstract. All studies reporting on single cases of AM or RM in eSTS, case-series and cohort studies focusing on diagnosis, treatment and outcome of AM and RM in eSTS were included. Studies containing patients with STS other than those located in the limbs were excluded. However, studies describing both patients with eSTS and abdominal STS or gastrointestinal stromal tumours (GIST), leiomyosarcoma of the uterus as well as bone sarcoma were included, given that a clear differentiation between eSTS and other STS/bone sarcomas was possible.

The main goal of the present study was to identify the rate of occurrence, diagnostic pathway and potential treatment strategies, as well as outcomes in eSTS patients with AM and RM.

Analysis

Due to limited data and the use of different reporting techniques, the present systematic review focused on descriptive analysis of the results included in articles.

RESULTS

Figure 1 shows the selection process of the articles, with 17 studies being included in the final descriptive analysis. Detailed study characteristics are presented in Table 1 for original articles reporting incidence ± diagnosis, therapy and outcome (n = 6), and in Table 2 for original articles (n = 3) and case reports (n = 8) focusing on diagnostic pathway, therapeutic procedures, or outcomes without allowing conclusions about the incidence of AM/RM. There were five original articles cantered on diagnosis of AM or RM in eSTS (including one article focusing on both diagnosis and treatment) and four articles describing therapeutic procedures in eSTS patients with AM or RM. An additional eight articles described case reports of AM/RM.

Table 1 Original articles (n = 6) analysing incidence of abdominal/retroperitoneal metastases in patients with extremity soft tissue sarcoma.

Ref.	Topic	Patients		(Prevalent) Histological subtype(s)	Chemotherapy/ radiotherapy	Outcome (after diagnosis of metastasis)
		Total number of STS (n), of whom eSTS, n (%)	Of whom eSTS with AM/RM, n (%)
Thompson et al[16], 2015	Diagnostic pathway	140 (100)	7 (5.0) AM	Epithelioid sarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma	N/A	N/A
King et al[9], 2009	Diagnostic pathway, outcome	124 (100)	7 (5.6) AM	MPNST, leiomyosarcoma, myxofibrosarcoma, pleomorphic sarcoma	N/A	21% mortality rate (n = 21/124)
Gorelik et al[6], 2018	Diagnostic pathway	33 (100)	4 (12.1) AM	Myxoid liposarcoma	89% of patients with metastases (including others than AM) received neoadj. RTX 22% received adj. RTX for primary tumour	N/A
Behranwala et al[8], 2004	Therapeutic approach	2127 (100)	19 (0.9) AM	Myxoid liposarcoma, leiomyosarcoma	CTX + RTX in 3 patients, and CTX or RTX in 1 patient each following resection of AM	Median OS: 12 mo
Ogose et al[11], 2000	Therapeutic approach	282 (100)	24 (8.5) AM	Liposarcoma	None of patients with AM received RTX or CTX	Mean OS (liver/GI metastases): 4.6 mo; Mean OS (pancreatic metastasis): 3.3 mo
Sheah et al[7], 2008	Diagnostic pathway	112 (100)	9 (8.0) AM; 2 (1.8) RM	Myxoid liposarcoma	N/A	N/A

AM: Abdominal metastasis; AWD: Alive with disease; DOD: Dead of disease; eSTS: Extremity soft tissue sarcoma; NED: No evidence of disease; OS: Overall survival; PFS: Progression-free survival; STS: Soft tissue sarcoma; CTX: Chemotherapy; RTX: Radiotherapy; N/A: Not applicable.

Figure 1 The selection process of the articles. eSTS: Extremity soft tissue sarcoma; DFSP: Dermatofibrosarcoma protuberans.

Table 2 Original articles (n = 3) and case reports (n = 8) exclusively reporting on patients developing abdominal or retroperitoneal metastases.

Ref.	Type	Topic	Patients	(Prevalent) Histological subtype(s)	Chemotherapy/ radiotherapy	Outcome (after diagnosis of metastasis)
Grimme et al[15], 2019	Original article	Therapeutic approach, outcome	38 patients with STS developing liver metastases [of whom 5 (13.2%) had been eSTS]	Leiomyosarcoma, liposarcoma	N/A	Median PFS: 16 mo Median OS: 46 mo
Lev-Chelouche et al[14], 2000	Original article	Diagnostic pathway, therapeutic approach	10 eSTS patients with RM	Liposarcoma	Adj. CTX in 4 patients, ± adj. RTX in 7 (details on combination of CTX/RTX not provided)	Mean OS: 13.3 mo
Rehders et al[23], 2009	Original article	Therapeutic approach	5 patients with eSTS (of 45 patients with STS) developing liver metastases	N/A	CTX following hepatic metastasectomy in 5 patients (no information whether eSTS or other STS)	44 mo (including both eSTS and other STS)
Sabel et al[19], 2001	Case report	N/A	58-yr-old male patient with small-bowel metastasis after 15 yr of follow-up	Alveolar soft part sarcoma	Adj. RTX for primary tumour, CTX for metastases (prior to development of AM)	N/A
Lee et al[18], 2010	Case report	N/A	23-yr-old male patient with gastric metastasis at 16 mo of follow-up	Alveolar soft part sarcoma	RTX for cerebral metastases, CTX declined by patient	DOD soon after metastasectomy (not specified by authors)
Koh et al[21], 2007	Case report	N/A	66-yr-old female with pancreatic metastasis soon after primary tumour diagnosis	Malignant mesenchymoma (70% osteosarcoma, 30% leiomyosarcoma)	CTX and RTX declined by patient	AWD at 9 mo
Mizoshiri et al[17], 2018	Case report	N/A	51-yr-old female with liver metastasis from leiomyosarcoma at 11 mo of follow-up	Leiomyosarcoma	Neoadj. + adj. CTX for primary tumour and CTX following hepatic metastasectomy in female patient	NED at 12 mo (male patient)
			60-yr-old male with liver metastasis from leiomyosarcoma at 3 yr of follow-up		Neoadj. + adj. CTX for male patient for primary tumour
Carboni et al[13], 2006	Case report	N/A	66-yr-old male patient with pancreatic metastasis at 6 yr of follow-up	Myxoid liposarcoma	Adjuvant RTX for local recurrence of primary tumour	NED at 6 mo
Watanabe et al[12], 2001	Case report	N/A	20-yr-old female patient with massive AM (37 cm diameter)	Myxoid liposarcoma	N/A	DOD (after several months, not specified by authors)
Lin et al[10], 2015	Case report	N/A	53-yr-old male patient with AM after 35 mo of follow-up	Myxoid liposarcoma	CTX and RTX for metastatic disease (prior to development of AM)	DOD after 3 mo
Willekens et al[20], 2011	Case report	N/A	27-yr-old female patient with duodenal metastasis	Alveolar soft part sarcoma	RTX for primary tumour	NED at 2 mo

AM: Abdominal metastasis; AWD: Alive with disease; DOD: Dead of disease; eSTS: Extremity soft tissue sarcoma; NED: No evidence of disease; OS: Overall survival; PFS: Progression-free survival; STS: Soft tissue sarcoma; CTX: Chemotherapy; RTX: Radiotherapy; N/A: Not applicable.

A potential bias was present in studies that concentrated exclusively on distinct histological subtypes (i.e., myxoid liposarcoma[6,7]). Moreover, case reports preferentially covered unusual and ”dramatic” clinical courses of eSTS patients with AM or RM.

The results of individual studies regarding patients included the prevalent histological subtypes and outcomes following diagnosis of AM or RM, and are provided in Tables 1 and 2.

Incidence

The incidence of AM following diagnosis of eSTS ranged from 0.9%[8]-5.6%[9] in patients with miscellaneous histological subtypes. In the case of eSTS with myxoid liposarcoma as the underlying histological subtype (which is known for its potential to metastasize to unusual sites), the incidence was higher, ranging from 9.8%[7]-12.1%[6].

Histological subtypes

The most prevalent histological subtypes with AM or RM were (myxoid) liposarcoma[6-8,10-15], leiomyosarcoma[8,9,15-17], and alveolar soft part sarcoma[18-20]. One case of pancreatic metastasis in malignant mesenchymoma (defined as a mesenchymal tumour composed of at least two malignant mesenchymal components) with 70% osteosarcoma and 30% leiomyosarcoma was identified as 100% derived from a leiomyosarcomatous origin[21,22]. Further rare histological subtypes presenting with AM or RM included epithelioid sarcoma[16], synovial sarcoma[16], malignant peripheral nerve sheath tumour[9], myxofibrosarcoma[9], and pleomorphic sarcoma[9].

Therapeutic approaches

In five out of eight reviewed case reports, surgery was performed for AM (62.5%)[13,17,19-21]. Among eSTS patients with AM/RM, 20.8%[11], 60%[14], 84.2%[8], and 100%[15,23] had undergone metastasectomy in the included retrospective case-series. In these studies, perioperative complication rates ranged from 20%[15]-44%[23]. Information on the administration of either RTX or CTX is provided in Tables 1 and 2.

Outcomes

Post-metastasis survival rates according to the individual studies are reported in Tables 1 and 2. In patients with hepatic metastases, overall survival (OS) appeared to be better if metastasectomies were performed (46 mo vs 4.6 mo for patients not undergoing metastasectomy)[11,15]. For patients with non-hepatic RM or AM, the reported survival rates were worse, ranging from 12-17.3 mo[8,14].

DISCUSSION

In this systematic review, the original articles that focused on AM or RM in patients with eSTS were analysed. In the following sections, results of the various included studies will be discussed in detail.

Incidence

Depending on the surveillance methods, the incidence of abdominal and RM varied: In the study by Behranwala et al[8], including over 2000 eSTS patients, the incidence of 0.9% for AM was lower than in other, smaller series, which reported rates of around 5%[9,16]. However, in the former study, abdominal CT scans were not routinely performed. Instead, these diagnostic measurements were implemented if patients were symptomatic. On the other hand, in the series of King et al[9] and Thompson et al[16], routine administration of CT scans of the thorax, abdomen and pelvis constituted the main inclusion criteria. Consequently, the study by Behranwala et al[8] may have underestimated the actual number of (asymptomatic) AM.

Moreover, in patients with myxoid liposarcoma as the underlying histological subtype, the incidence of AM/RM was significantly higher, at 9.8% and 12.1% in studies by Sheah et al[7] and Gorelik et al[6], respectively. As myxoid liposarcomas are known to metastasize to unusual locations[24], whole-body MRI has been suggested as a sensitive screening and follow-up imaging technique in patients with eSTS of this specific histological subtype[7,11]. This sensitive method may have further increased the detection rate of AM/RM during follow-up.

Histology

Myxoid liposarcoma was the most prevalent histological subtype to develop AM/RM, followed by leiomyosarcoma and alveolar soft part sarcoma; in nine of the seventeen studies, AM or RM originated from myxoid liposarcomas of the extremities[6-8,10-15].

Therapeutic approaches

Five studies specifically focused on therapeutic approaches in AM or RM[8,11,14,15,23]. In the study by Rehders et al[23], the outcome of 45 patients with STS, of whom five have had eSTS, and subsequently developed hepatic metastases, was analysed. All patients had undergone surgical resection of their metastases, most commonly wedge resections (n = 8) and hemihepatectomies (n = 7). Comparable results were reported by Grimme et al[15], including 5 eSTS patients and a further 33 patients with STS at other sites, who developed liver metastases. Most patients in their cohort (n = 24) underwent a minor resection, defined as ≤ 2 segments of the liver, whilst 13 patients were treated by major hepatic resection[15]. Three patients had intraoperative complications (i.e., small-bowel perforation, tumour rupture, bleeding), and 6 patients developed postoperative complications, resulting in a perioperative complication rate of 20%[15]. Slightly more complications were reported by Rehders et al[23], with a combined complication rate of 44%, including 7 minor complications (i.e., not requiring surgical intervention) and 5 major complications (i.e., requiring surgical interventions or proving fatal).

Of the 19 eSTS patients with AM analysed in the study by Behranwala et al[8], 16 patients (84.2%) underwent abdominal metastasectomy. Of these, three subsequently developed abdominal recurrences[8]. All 14 patients with liver metastases in the study by Ogose et al[11] were treated conservatively. Of the 10 patients with non-hepatic AM, 4 were treated conservatively, 5 patients underwent abdominal metastasectomy, and one further patient was treated by RTX[11]. The rate or type of complications were not reported in these two studies.

In the study by Lev-Chelouche et al[14], 6 out of 10 patients with RM underwent curative metastasectomy, accompanied by extensive intra-abdominal resection (colectomy, nephrectomy, splenectomy, sigmoidectomy, pancreatectomy) in 4 patients. A further two patients showed diffuse metastatic disease infiltrating the mesentery root, resulting in only diagnostic laparotomy[14]. These were treated with CTX, along with two further patients who were considered inoperable[14].

In five out of eight case reports, metastasectomy was performed for AM following eSTS diagnosis[13,17,19-21]. In a single further case, embolization was performed for bleeding gastric metastases[18]. In the remaining two cases, multiple metastases and irresectable AM lead to a conservative approach[10,12].

Outcomes

Resection of the abdominal or RM was associated with a survival benefit compared to patients treated by CTX. In the study by Ogose et al[11], none of the patients with eSTS liver metastases had undergone surgery, resulting in a mean OS of 4.6 mo. On the other hand, liver resection was performed in all 5 patients in the study by Grimme et al[15] with a median OS of 46 mo (including results from liver metastases of 33 STS patients with non-extremity primary tumours). Comparable results were observed by Rehders et al[23], with a median OS of 44 mo following metastasectomy for liver metastases. Notably, patients with RM or AM not confined to the liver had poorer post-metastasectomy survival rates. OS was limited to a median of 12 mo in the study by Behranwala et al[8], including 19 patients with AM, although 16 of them had undergone metastasectomy. Comparable rates were observed by Lev-Chelouche et al[14] in 10 patients with RM, of whom 6 had undergone surgery with a curative intent, and 4 had been treated by CTX. Mean OS was 13.3 mo for all patients and 17.3 mo for those patients treated with a curative intent, compared to 5.8 mo for the 4 patients undergoing CTX[14]. It could be argued that patients undergoing metastasectomy were generally in better condition, thereby improving their prognosis. However, according to a recently published retrospective study, even when confounding factors such as physical performance status, number of metastases and laboratory parameters (e.g., haemoglobin and albumin levels) are considered, metastasectomies result in a significant survival benefit[25].

One limitation of the present review is that studies not clearly differentiating between STS subtypes (i.e., GIST, leiomyosarcoma of the uterus, extremity STS) had to be excluded from the present review. Furthermore, only two studies reported on eSTS patients developing RM. Considering that AM and RM are diagnosed and treated similarly, conclusions from the present systematic review are most likely applicable to both.

In conclusion, depending on the surveillance method used, up to 12.1% of eSTS patients with myxoid liposarcoma and 5.6% of eSTS patients with other histological subtypes develop AM/RM during their follow-up. Patients with myxoid liposarcoma in particular seem to benefit from regular follow-up with whole-body MRI, as metastases to sites other than the lung (including bone and abdomen/ retroperitoneum) can be detected with higher sensitivity. In cases where patients with eSTS develop metastases to the abdomen or retroperitoneum, wide resection should be attempted whenever feasible. Particularly for patients with hepatic metastases, high post-metastasectomy survival rates over a long period have been reported. However, patients with AM at other sites or RM also seem to benefit from metastasectomy in terms of survival.

Consequently, regular abdominal ultrasonography and CT scans should be performed in eSTS patients. Moreover, in myxoid liposarcoma, whole-body MRI may be administered in order to detect AM, RM or metastases at other unusual sites at an early – and potentially resectable - stage.

ARTICLE HIGHLIGHTS

Research background

Currently, there is no clear consensus on the best imaging modality or follow-up duration for patients with primary extremity soft tissue sarcoma (eSTS), which is important to detect metastases to unusual sites, including the abdomen and retroperitoneum.

Research motivation

There is limited knowledge on incidence, treatment and outcome of abdominal metastases (AM) and retroperitoneal metastases (RM) in patients with primary eSTS undergoing surgery with curative intent.

Research objectives

The objective of the present systematic review was to summarise current knowledge on incidence, diagnosis, treatment and outcome of AM and RM in eSTS patients.

Research methods

A systematic literature review was performed, screening all studies published in PubMed between January, 2000 and December, 2018 adhering to the PRISMA guidelines. Of 899 articles screened, 17 were eligible to be included in the present review.

Research results

Six original articles of the 17 studies provided information on incidence ± diagnosis, therapy and outcome, whilst three original articles and eight case reports did not allow for conclusions on the incidence of AM/RM. Incidence of AM/RM ranged between 0.9%-12.1%, depending on the underlying histological subtype. (Myxoid) liposarcoma and leiomyosarcoma were the prevalent histological subtypes, although rare entities had also been reported to develop AM/RM. Surgery was performed in 62.5% of case reports and in 20.8%-100.0% of original articles, with patients undergoing metastasectomy having an improved outcome. Especially in patients with hepatic metastases, metastasectomy was associated with improved post-metastasis survival.

Research conclusions

Abdominal ultrasonography/ computed tomography (CT) should be performed on a regular basis during follow-up in eSTS patients. In patients with a high risk of developing AM/RM– especially those with myxoid liposarcoma – even whole-body magnetic resonance imaging may be considered.

Research perspectives

Prospective studies investigating the effect of surveillance with abdominal ultrasonography or CT scans of the abdomen for reporting incidences of AM/RM as well as patient outcome are warranted.